Ten-Year Outcomes of End-Stage Kidney Disease - EMG

Ten-Year Outcomes of End-Stage Kidney Disease

1 Mins

THE NUMBER of Canadians living with end-stage kidney disease (ESKD) is on the rise, having increased by 35% from 2008–2017, affecting >38,800 people (not including patients from Québec); as a result, this condition is highly pertinent. A comparison of dialysis and kidney transplants, based on Canadian data, has shown there are major differences in long-term outcomes between the two treatments in individuals with ESKD. The Canadian Institute for Health Information (CIHI) released 10-year outcome data on the two treatments. The data showed that up to 74% of Canadians who received a kidney transplant still had a functioning kidney a decade after the surgery, while 84% of Canadians on dialysis did not survive >10 years. It is worth highlighting that patients who had their transplanted kidney begin to fail would still have had the treatment option of dialysis.

Closer analysis revealed that age was also a major factor in determining the outcome of ESKD treatment. Of those Canadians aged from 18–44 years at the onset of dialysis, 51% survived past 10 years. The corresponding figure for those aged 65–74 years was 12%. A similar trend was observed for 10-year kidney transplant outcomes. The percentage of Canadians receiving a transplant who had a functioning kidney after 10 years was 80% for those aged 18–44 and up to 64% for those who were >65.  Additionally, kidneys donated by deceased donors tended to function effectively for less time than kidneys transplanted from a living donor.

There was an increased trend of deceased organ donations from 2008–2017, with a 51% increase; however, the rate of living donation decreased by 11%. At present, 4,333 patients are on the waiting list for a kidney transplant. With this shortage of donated kidneys, the data makes it even more imperative to design policies that encourage organ donation.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now